

EMA/513383/2023

European Medicines Agency decision P/0530/2023

of 29 December 2023

on the acceptance of a modification of an agreed paediatric investigation plan for meropenem / vaborbactam (Vaborem), (EMEA-001731-PIP01-14-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0530/2023

of 29 December 2023

on the acceptance of a modification of an agreed paediatric investigation plan for meropenem / vaborbactam (Vaborem), (EMA-001731-PIP01-14-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0229/2015 issued on 22 October 2015, the decision P/0267/2020 issued on 15 July 2020 and the decision P/0260/2021 issued on 9 July 2021,

Having regard to the application submitted by Menarini International Operations Luxembourg S.A. on 31 July 2023 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 10 November 2023, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for meropenem / vaborbactam (Vaborem), powder for concentrate for solution for infusion, intravenous use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Menarini International Operations Luxembourg S.A., 1, Avenue de la Gare, L-1611 – Luxembourg, Luxembourg.

EMA/PDCO/362992/2023
Amsterdam, 10 November 2023

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-001731-PIP01-14-M04

Scope of the application

Active substance(s):

Meropenem / vaborbactam

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of Gram-negative bacterial infections

Pharmaceutical form(s):

Powder for concentrate for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Menarini International Operations Luxembourg S.A.

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Menarini International Operations Luxembourg S.A. submitted to the European Medicines Agency on 31 July 2023 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0229/2015 issued on 22 October 2015, the decision P/0267/2020 issued on 15 July 2020 and the decision P/0260/2021 issued on 9 July 2021.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 11 September 2023.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric investigation plan

2.1. Condition:

Treatment of Gram-negative bacterial infections

2.1.1. Indication(s) targeted by the PIP

Treatment of complicated urinary tract infection (cUTI) including pyelonephritis

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Powder for concentrate for solution for infusion

2.1.4. Measures

Area	Description
Quality-related studies	Study 1 Development of an age-appropriate formulation for intravenous use
Non-clinical studies	Study 2 Dose-range finding study to support dose-selection for the main juvenile toxicity study and to determine maximum tolerated dose of combination Study 3 Definitive juvenile toxicity study to assess toxicity of vaborbactam in combination with meropenem in juvenile animals and to evaluate delayed onset of toxicity and recovery from possible toxic effects during the recovery period
Clinical studies	Study 4 Open-label, single dose trial to evaluate pharmacokinetics, safety and tolerability study of meropenem in combination with vaborbactam in children from birth to less than 18 years of age with confirmed or suspected bacterial infections requiring intravenous antibiotics Study 5 Study deleted in EMEA-001731-PIP01-14-M03

	Study 6 Open-label, multiple-dose, active controlled trial to evaluate pharmacokinetic, safety and tolerability study of meropenem in combination with vaborbactam in neonates from birth to less or equal than 90 days with late onset sepsis. Study 8 Study added in EMEA-001731-PIP01-14-M03 Open label trial to evaluate pharmacokinetics, safety and efficacy of meropenem in combination with vaborbactam in children from 3 months to less than 18 years of age with complicated urinary tract infections (cUTI) including acute pyelonephritis (AP).
Extrapolation, modelling and simulation studies	Study 7 Population PK/PD modelling and simulation study for dose selection across paediatric age groups for patients with infections caused by Gram-negative bacteria.
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By December 2026
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s)

1. Treatment of Treatment of Gram-negative bacterial infections

Authorised indication(s):

- Complicated urinary tract infection (cUTI), including pyelonephritis
 - Invented name(s): Vaborem
 - Authorised pharmaceutical form(s): powder for concentrate for solution for infusion (powder for concentrate)
 - Authorised route(s) of administration: intravenous use
 - Authorised via centralised procedure
 - Complicated intra-abdominal infection (cIAI)
 - Invented name(s): Vaborem
 - Authorised pharmaceutical form(s): powder for concentrate for solution for infusion (powder for concentrate)
 - Authorised route(s) of administration: intravenous use
 - Authorised via centralised procedure
 - Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP).
 - Invented name(s): Vaborem
 - Authorised pharmaceutical form(s): powder for concentrate for solution for infusion (powder for concentrate)
 - Authorised route(s) of administration: intravenous use
 - Authorised via centralised procedure
2. Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.

Authorised indication(s):

- Vaborem is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
 - Invented name(s): Vaborem
 - Authorised pharmaceutical form(s): powder for concentrate for solution for infusion (powder for concentrate)
 - Authorised route(s) of administration: intravenous use
 - Authorised via centralised procedure